TRxADE HEALTH, Inc.
MEDS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | -0.00 | -1.20 | -0.09 |
| FCF Yield | -56.88% | -52.19% | -57.94% | -13.48% |
| EV / EBITDA | -1.39 | -0.95 | -2.09 | -3.36 |
| Quality | ||||
| ROIC | -17.86% | -94.99% | -143.09% | -101.83% |
| Gross Margin | 4.39% | 31.41% | 47.62% | 47.99% |
| Cash Conversion Ratio | 0.71 | 0.15 | 0.39 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -77.15% | -5.78% | -12.56% | 9.97% |
| Free Cash Flow Growth | -540.73% | -4.90% | 23.64% | -14.94% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | -0.61 | -0.24 | 0.36 |
| Interest Coverage | 14.06 | -6.06 | -8.20 | -224.34 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 5,861.53 | 50.15 | 91.39 |
| Cash Conversion Cycle | 2,986.26 | -23.90 | -4.77 | 6.27 |